Department of Pharmacology, Toxicology and Therapeutic Chemistry (Pharmacology Section) and Institute of Neuroscience, University of Barcelona and CIBERNED, Barcelona, Spain.
Institut d'Investigacions Biomèdiques de Barcelona (IIBB), CSIC, IDIBAPS and CIBERESP, Barcelona, Spain.
J Alzheimers Dis. 2018;62(3):943-963. doi: 10.3233/JAD-170664.
Epigenetics is emerging as the missing link among genetic inheritance, environmental influences, and body and brain health status. In the brain, specific changes in nucleic acids or their associated proteins in neurons and glial cells might imprint differential patterns of gene activation that will favor either cognitive enhancement or cognitive loss for more than one generation. Furthermore, derangement of age-related epigenetic signaling is appearing as a significant risk factor for illnesses of aging, including neurodegeneration and Alzheimer's disease (AD). In addition, better knowledge of epigenetic mechanisms might provide hints and clues in the triggering and progression of AD. Intense research in experimental models suggests that molecular interventions for modulating epigenetic mechanisms might have therapeutic applications to promote cognitive maintenance through an advanced age. The SAMP8 mouse is a senescence model with AD traits in which the study of epigenetic alterations may unveil epigenetic therapies against the AD.
表观遗传学正在成为遗传继承、环境影响以及身体和大脑健康状况之间缺失的环节。在大脑中,神经元和神经胶质细胞中核酸或其相关蛋白的特定变化可能会产生不同的基因激活模式,从而有利于一代以上的认知增强或认知丧失。此外,与年龄相关的表观遗传信号失调似乎是衰老相关疾病(包括神经退行性疾病和阿尔茨海默病(AD))的一个重要危险因素。此外,对表观遗传机制的更好了解可能会为 AD 的触发和进展提供线索。实验模型的深入研究表明,调节表观遗传机制的分子干预可能具有治疗应用,可通过先进的年龄来促进认知维持。SAMP8 小鼠是一种具有 AD 特征的衰老模型,对其进行表观遗传改变的研究可能会揭示针对 AD 的表观遗传治疗方法。